At last year’s inaugural “Famous Hoosiers” program Richard Gunderman made a moving and very well received presentation about ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro pen, its widely used diabetes and weight-loss drug. Available in six dosages, Mounjaro helps manage type 2 ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, intensifying the race for India's booming obesity drug market.

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.

Bernstein SocGen Group has reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) ahead of the American Diabetes Association’s 85th Annual meeting.

In recent times, though, Lilly has become less expensive, as the stock slipped 12% from a high reached in March. Is Lilly a buy on the dip? Let's find out. Image source: Getty Images.

U.S. pharmaceutical company Eli Lilly (LLY) has partnered with Juvena Therapeutics on a new muscle-boosting drug. Confident Investing Starts Here: Easily unpack a company's performance with ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the ...

Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Earlier this week, Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion. The acquisition will add Verve’s pipeline of gene ...